Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 135

Sort by

Sort Order Select

Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood (2024) 144 (17): 1813–1820.

https://doi.org/10.1182/blood.2024025802

Published: 2024

Journal Articles

Introduction to a review series on RNA therapeutics in hematology

Jason Gotlib

Blood (2023) 142 (19): 1577–1579.

https://doi.org/10.1182/blood.2023020910

Published: 2023

Journal Articles

Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the Post-Venetoclax Era

Emma C St. Martin, Matthew Schwede, Bita Fakhri, Jason Gotlib, Michaela Liedtke, William Shomali, Tian Y. Zhang, Gabriel Mannis

Blood (2023) 142 (Supplement 1): 1490.

https://doi.org/10.1182/blood-2023-190614

Published: 2023

Journal Articles

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Blood (2023) 142 (Supplement 1): 624.

https://doi.org/10.1182/blood-2023-179291

Published: 2023

Journal Articles

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

Blood (2023) 142 (Supplement 1): 4551.

https://doi.org/10.1182/blood-2023-180945

Published: 2023

Journal Articles

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Andrew T. Kuykendall, Somedeb Ball, Jason Gotlib, Cecilia Y. Arana Yi, Tsewang Tashi, Raajit K. Rampal, Daniel J. DeAngelo, Virginia O. Volpe, Kristen Marie Pettit, Rami S. Komrokji, Eric Padron

Blood (2023) 142 (Supplement 1): 6441.

https://doi.org/10.1182/blood-2023-184652

Published: 2023

Journal Articles

Cladribine and Low-Dose Cytarabine-Based Salvage Therapy for Relapsed/Refractory AML in a Predominantly Venetoclax-Exposed Cohort

Edna Cheung, Claire Schumann, Tian Y. Zhang, Bita Fakhri, Jason Gotlib, Michaela Liedtke, William Shomali, Gabriel Mannis

Blood (2023) 142 (Supplement 1): 5927.

https://doi.org/10.1182/blood-2023-185524

Published: 2023

Journal Articles

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2023-187092

Published: 2023

Journal Articles

Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis

Chen Zhang, Douglas Tremblay, John Magnotti, Lukas Ronner, Nikolai A. Podoltsev, Jason Gotlib, Mark L. Heaney, Andrew Kuykendall, Casey L. O'Connell, Angela G Fleischman, Ruben Mesa, Abdulraheem Yacoub, John Mascarenhas, Jamile M. Shammo

Blood (2022) 140 (Supplement 1): 9693–9695.

https://doi.org/10.1182/blood-2022-157873

Published: 2022

Journal Articles

AZURE: A Phase 1/2 Study of Blu-263 As Monotherapy and in Combination with Azacitidine in Patients with Advanced Systemic Mastocytosis

Daniel J. DeAngelo, Andreas Reiter, Tracy I. George, Deepti H. Radia, Marissa Devlin, Saša Dimitrijević, Mikael Rinne, Robyn Scherber, Jason Gotlib

Blood (2022) 140 (Supplement 1): 6877–6878.

https://doi.org/10.1182/blood-2022-167410

Published: 2022

Journal Articles

An Updated Analysis on Safety and Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis from the Explorer Clinical Study: Long-Term Efficacy and Safety

Daniel J. DeAngelo, Deepti H. Radia, Tracy I. George, William A. Robinson, Albert T. Quiery, Mark W. Drummond, Prithviraj Bose, Elizabeth O. Hexner, Elliott Winton, Hans-Peter Horny, Meera Tugnait, Hui-Min Lin, Saša Dimitrijević, Javier I. Munoz-Gonzalez, Ilda Bidollari, Michael W. Deininger, Jason Gotlib

Blood (2022) 140 (Supplement 1): 3932–3934.

https://doi.org/10.1182/blood-2022-167593

Published: 2022

Journal Articles

Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Cem Akin, Frank Siebenhaar, Michael W. Deininger, Daniel J. DeAngelo, Tracy I. George, Mariana Castells, Matthew Giannetti, Jason Gotlib, Jessica Sachs, Amanda Pilla, Hina A. Jolin, Prithviraj Bose

Blood (2022) 140 (Supplement 1): 6838–6839.

https://doi.org/10.1182/blood-2022-156326

Published: 2022

Journal Articles

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

Blood (2022) 140 (Supplement 1): 821–823.

https://doi.org/10.1182/blood-2022-160409

Published: 2022

Journal Articles

Avapritinib As First-Line Therapy in Patients with Advanced Systemic Mastocytosis: Efficacy and Safety from the Pathfinder Clinical Study

Deepti H. Radia, Jason Gotlib, Mark W. Drummond, Tracy I. George, Hui-Min Lin, Saša Dimitrijević, Javier I. Munoz-Gonzalez, Ilda Bidollari, Michael W. Deininger, Daniel J. DeAngelo, Andreas Reiter

Blood (2022) 140 (Supplement 1): 1509–1511.

https://doi.org/10.1182/blood-2022-166986

Published: 2022

Journal Articles

FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 ( FGFR1 ) Rearrangement (MLN FGFR1 ): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients

Srdan Verstovsek, Jason Gotlib, Alessandro M. Vannucchi, Alessandro Rambaldi, Andreas Reiter, William Shomali, Tracy I. George, Jay L. Patel, Philomena Colucci, Huiling Zhen, Natalia Oliveira, Jean-Jacques Kiladjian

Blood (2022) 140 (Supplement 1): 3980–3982.

https://doi.org/10.1182/blood-2022-163099

Published: 2022

Journal Articles

Rusfertide for Polycythemia Vera: Similar Dosing in Patients Receiving Therapeutic Phlebotomy Alone or in Combination with Cytoreductive Treatment

Aaron T. Gerds, Jason Gotlib, Jeanne M. Palmer, Naveen Pemmaraju, Prithviraj Bose, Yelena Ginzburg, Frank Valone, Nishit B. Modi, Sarita Khanna, Paula G. O'Connor, Suneel K. Gupta, Ronald Hoffman

Blood (2022) 140 (Supplement 1): 12241–12243.

https://doi.org/10.1182/blood-2022-163847

Published: 2022

Journal Articles

Avapritinib for advanced systemic mastocytosis

Jason Gotlib, Andreas Reiter, Daniel J. DeAngelo

Blood (2022) 140 (15): 1667–1673.

https://doi.org/10.1182/blood.2021014612

Published: 2022

Journal Articles

Whole-genome CRISPR screening identifies N- glycosylation as a genetic and therapeutic vulnerability in CALR -mutant MPNs

Jonas S. Jutzi, Anna E. Marneth, Michele Ciboddo, Angel Guerra-Moreno, María José Jiménez-Santos, Anastasia Kosmidou, James W. Dressman, Hongyan Liang, Rebecca Hamel, Patricia Lozano, Elisa Rumi, John G. Doench, Jason Gotlib, Anandi Krishnan, Shannon Elf, Fátima Al-Shahrour, Ann Mullally

Blood (2022) 140 (11): 1291–1304.

https://doi.org/10.1182/blood.2022015629

Published: 2022

Includes: Supplemental data

Journal Articles

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi

Blood (2022) 140 (11): 1200–1228.

https://doi.org/10.1182/blood.2022015850

Published: 2022

Includes: Supplemental data

Journal Articles

Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth

Jason Gotlib

Blood (2022) 139 (19): 2871–2881.

https://doi.org/10.1182/blood.2022015680

Published: 2022

NARROW

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Introduction to a review series on RNA therapeutics in hematology

Analysis of Treatment Patterns and Outcomes in Patients Ages 60-74 in the Post-Venetoclax Era

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Deep and Durable Cytogenetic and Molecular Responses with Pemigatinib in Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement: The Fight-203 Study

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Cladribine and Low-Dose Cytarabine-Based Salvage Therapy for Relapsed/Refractory AML in a Predominantly Venetoclax-Exposed Cohort

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Exploratory Predictors for Hydroxyurea Treatment Duration in Polycythemia Vera: A Retrospective Multi-Institutional Database Analysis

AZURE: A Phase 1/2 Study of Blu-263 As Monotherapy and in Combination with Azacitidine in Patients with Advanced Systemic Mastocytosis

An Updated Analysis on Safety and Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis from the Explorer Clinical Study: Long-Term Efficacy and Safety

Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

Avapritinib As First-Line Therapy in Patients with Advanced Systemic Mastocytosis: Efficacy and Safety from the Pathfinder Clinical Study

FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 ( FGFR1 ) Rearrangement (MLN FGFR1 ): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients

Rusfertide for Polycythemia Vera: Similar Dosing in Patients Receiving Therapeutic Phlebotomy Alone or in Combination with Cytoreductive Treatment

Avapritinib for advanced systemic mastocytosis

Whole-genome CRISPR screening identifies N- glycosylation as a genetic and therapeutic vulnerability in CALR -mutant MPNs

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only